Literature DB >> 413639

A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.

M H Wahdan, S A Sallam, M N Hassan, A Abdel Gawad, A S Rakha, J E Sippel, R Hablas, W R Sanborn, N M Kassem, S M Riad, B Cvjetanović.   

Abstract

The encouraging results of an earlier controlled field trial of the serogroup A meningococcal polysaccharide vaccine in the prevention of clinical disease prompted this study, the aim of which was to evaluate further the effectiveness of another lot of this type of vaccine, the duration of immunity, and the effectiveness against meningococcal carriage. A controlled field trial was carried out in early 1973 on 176 646 schoolchildren 6-15 years of age, of whom half received the serogroup A polysaccharide vaccine and the other half tetanus toxoid as a control. The incidence of cerebrospinal meningitis caused by serogroup A meningococci was 89% lower in the immunized group than in the controls for one year only. With regard to its effect on carriage, the vaccine was found to reduce to less than half the rate of new acquisition of serogroup A meningococci during the period immediately following immunization. The duration of the carrier state was also shortened in the immunized group.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 413639      PMCID: PMC2366720     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70.

Authors:  R Gold; M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

2.  Meningococcal infections. 3. Studies of group A polysaccharide vaccines.

Authors:  M S Artenstein; W C Branche; J G Zimmerly; R L Cohen; E C Tramont; D L Kasper; C Harkins
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

3.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.

Authors:  M H Wahdan; F Rizk; A M el-Akkad; A A el-Ghoroury; R Hablas; N I Girgis; A Amer; W Boctar; J E Sippel; E C Gotschlich; R Triau; W R Sanborn; B Cvjetanović
Journal:  Bull World Health Organ       Date:  1973-06       Impact factor: 9.408

4.  A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A.

Authors:  H H Erwa; M A Haseeb; A A Idris; L Lapeyssonnie; W R Sanborn; J E Sippel
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

  4 in total
  15 in total

Review 1.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 4.  Current status--meningococcal vaccine.

Authors:  R Merchant; R Divekar
Journal:  Indian J Pediatr       Date:  1988 Mar-Apr       Impact factor: 1.967

5.  Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Part II. Epidemiological models of acute bacterial diseases.

Authors:  B Cvjetanović; B Grab; K Uemura
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

6.  Epidemic group C meningococcal meningitis in Upper Volta, 1979.

Authors:  C V Broome; M A Rugh; A A Yada; L Giat; H Giat; J M Zeltner; W R Sanborn; D W Fraser
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

7.  Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults.

Authors:  J M Griffiss; B L Brandt; P L Altieri; G B Pier; S L Berman
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

8.  Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine.

Authors:  H Käyhty
Journal:  J Clin Microbiol       Date:  1980-08       Impact factor: 5.948

9.  Immunization during a cerebrospinal meningitis epidemic in the Mongolian People's Republic, 1974-75.

Authors:  G Jamba; B Bytchenko; G Causse; B Cvjetanović; G Ocirvan; N Tsend; J Kupul; S Tseren; A Batsuri; A Hisigdorj; V Burian
Journal:  Bull World Health Organ       Date:  1979       Impact factor: 9.408

Review 10.  Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt.

Authors:  Lamyaa Shaban; Rania Siam
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-09-24       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.